IL6 and ovarian carcinoma: Supporting our findings, clinical studies have shown that elevated IL-6 serum levels correlate with worse patient outcomes [13, 36], and targeting IL-6 signaling with a neutralizing antibody has shown promising results in a clinical trial for the treatment of ovarian cancer [33].